Curacyte AG is an advanced biopharmaceutical company dedicated to the
development of new therapeutics for acute and critical care. After the recent sale of its
preclinical technology platform for low molecular weight protease inhibitors to The Medicines
Company, Curacyte has focussed all its efforts
on the development of PHP / Hemoximer.
Apart from distriutive shock, Hemoximer is also being studied as an adjunct to high-dose
interleukin-2 (IL-2) for patients with metastatic melanoma and renal cell carcinoma. Shock is a
frequent dose-limiting side effect of high-dose IL-2 therapy.
|
|||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||
|
|
|
|
|
||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||